Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma
- PMID: 33674443
- DOI: 10.1158/1541-7786.MCR-20-0917
Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma
Abstract
The tumor microenvironment (TME) plays a key role in the efficacy of neoadjuvant chemotherapy (NAC) in solid tumors including esophageal squamous cell carcinoma (ESCC). However, the TME profile of ESCC treated with NAC is not fully understood. In this study, we investigated the effect of NAC on the TME especially tumor-associated macrophages (TAM), the important immunosuppressive components of the TME, in ESCC. We quantified the expression of CD163, a crucial marker of TAM, in pretherapeutic biopsy and surgically resected ESCC specimens from patients who received NAC (n = 33) or did not receive NAC (n = 12). We found that NAC dramatically increased the expression of CD163 on TAMs in ESCC. Colony-stimulating factor 1 (CSF-1) and IL34 are crucial cytokines that recruit monocytes into tumor sites and differentiate them into TAMs. Interestingly, NAC significantly upregulated the expression of IL34 but not CSF-1 on tumor cells, and the frequencies of CD163+ TAMs were significantly correlated with IL34 expression in ESCC after NAC. The expression of IL34 in NAC-nonresponsive patients was significantly higher than that in NAC-responsive patients, and patients with IL34-high ESCC exhibited worse prognosis as compared with patients with IL34-low ESCC. We also demonstrated that 5-fluorouracil (5-FU)/cisplatin preferentially increased mRNA expression of IL34 on human ESCC cell lines. Human peripheral blood monocytes co-cultured with ESCC cells treated with 5-FU/cisplatin increased the expression of CD163, which was attenuated by the treatment with CSF-1R inhibitors. These data suggest that IL34 expression by NAC shifts the TME toward CD163+ TAM-rich immunosuppressive and chemo-insensitive microenvironment in ESCC. IMPLICATIONS: The blockade of IL34 signaling may offer a novel therapeutic strategy against chemoresistance in ESCC by inhibiting M2-TAM polarization.
©2021 American Association for Cancer Research.
Similar articles
-
Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.Cancer Sci. 2020 Apr;111(4):1103-1112. doi: 10.1111/cas.14328. Epub 2020 Feb 18. Cancer Sci. 2020. PMID: 31981293 Free PMC article.
-
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.Br J Cancer. 2011 Feb 15;104(4):707-13. doi: 10.1038/sj.bjc.6606071. Epub 2011 Jan 4. Br J Cancer. 2011. PMID: 21206495 Free PMC article.
-
Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.Int Immunopharmacol. 2021 Jul;96:107616. doi: 10.1016/j.intimp.2021.107616. Epub 2021 May 28. Int Immunopharmacol. 2021. PMID: 34162127
-
[Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].Gan To Kagaku Ryoho. 2015 Apr;42(4):497-501. Gan To Kagaku Ryoho. 2015. PMID: 25963701 Review. Japanese.
-
Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications.Biomed Pharmacother. 2023 Nov;167:115610. doi: 10.1016/j.biopha.2023.115610. Epub 2023 Sep 30. Biomed Pharmacother. 2023. PMID: 37783153 Review.
Cited by
-
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.Cancer Immunol Immunother. 2023 Apr;72(4):851-864. doi: 10.1007/s00262-022-03293-3. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36104597 Free PMC article.
-
Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.Cancers (Basel). 2023 Feb 3;15(3):971. doi: 10.3390/cancers15030971. Cancers (Basel). 2023. PMID: 36765929 Free PMC article. Review.
-
The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.Ann Med. 2025 Dec;57(1):2447403. doi: 10.1080/07853890.2024.2447403. Epub 2025 Jan 6. Ann Med. 2025. PMID: 39757995 Free PMC article. Review.
-
M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma.J Transl Med. 2023 Jan 14;21(1):26. doi: 10.1186/s12967-022-03863-0. J Transl Med. 2023. PMID: 36641471 Free PMC article.
-
Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation.iScience. 2025 May 26;28(6):112752. doi: 10.1016/j.isci.2025.112752. eCollection 2025 Jun 20. iScience. 2025. PMID: 40538439 Free PMC article.
References
-
- Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
-
- Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
-
- Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416.
-
- Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.
-
- Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117:1583–91.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous